Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture

Sponsor
China Academy of Chinese Medical Sciences (Other)
Overall Status
Unknown status
CT.gov ID
NCT03343262
Collaborator
(none)
158
2
36

Study Details

Study Description

Brief Summary

Impaired Glucose Tolerance (IGT) is an abnormal metabolic state following glucose metabolic steady state but prior to diabetes. IGT is an important stage during the progression of diabetes, with an underlying mechanism of insulin resistance and pancreatic β cell dysfunction. IGT is one of the diseases that shows significant beneficial response to acupuncture treatment. Original findings from the investigators'laboratory show that transcutaneous auricular vagus nerve stimulation (taVNS) which is innervated by vagus nerve, would enhance the activity of pancreatic β cells, promote the secretion of insulin, upregulate the expression of insulin receptors in central as well as peripheral tissues, thus to improve glycometabolism. In this study, the investigators would further illuminate the mechanism of taVNS at "yidan-pi" auricular acupoints on the regulation of glucose metabolism, its improvement of the IGT state in rat model, as well as its regulation effect on insulin receptor expression and insulin resistance, and systematically illustrate the clinical effective of this treatment on IGT, with emphasize on its influence on the concentrations of glucose and HbA1c, and thus provide an effective proposal for clinical acupuncture.

Condition or Disease Intervention/Treatment Phase
  • Device: ta-VNS
  • Other: Electro-acupuncture
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
158 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture
Anticipated Study Start Date :
Jan 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2019
Anticipated Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: ta-VNS "yidan-pi"

Device:ta-VNS & Electro-acupuncture("yidan-pi" auricular acupoints):2 times per day,2 days per week for 12 weeks

Device: ta-VNS
The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
Other Names:
  • transcutaneous vagus nerve stimulation
  • Other: Electro-acupuncture
    one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.

    Placebo Comparator: ta-VNS "jian"

    Device:ta-VNS & Electro-acupuncture("jian" auricular acupoints):2 times per day,2 days per week for 12 weeks

    Other: Electro-acupuncture
    one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.

    Outcome Measures

    Primary Outcome Measures

    1. FPG [Baseline and 6 week, 12 weeks]

      The fasting plasma glucose (FPG) is used to diagnose diabetes. IGT can be diagnosed base on FPG less than 7.0 mmol/L.

    2. OGGT [Baseline and 6 week, 12 weeks]

      The 2-hour plasma glucose after a 75-g oral glucose tolerance test (OGTT) is used to diagnose diabetes. IGT can be diagnosed base on 2-hour plasma Glucose between 7.8 and 11.1 mmol/L.

    Secondary Outcome Measures

    1. BMI [Baseline and 12 weeks]

      The body mass index are used to diagnose Obesity. Weight and height will be combined to report BMI in kg/m^2

    2. A1C [Baseline and 6 week,baseline and 12 weeks]

      The hemoglobin A1C (A1C) is a diagnostic test for diabetes. Diabetes can be diagnosed base on A1C more than 6.5%.

    Other Outcome Measures

    1. pulse [Baseline and 12 weeks]

      Normal pulse should be more than 60 per minute, or less than 100 per minute.

    2. respiration [Baseline and 12 weeks]

      Normal respiration should be more than 16 times, or less than 20 times.

    3. blood pressure [Baseline and 12 weeks]

      The systolic pressure should be no more than 139 mmHG, and the diastolic pressure should be no less than 89 mmHg.

    4. body temperature [Baseline and 12 weeks]

      Normal temperature should be more than 36 C, or less than 37 C.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ages between 20 and 70

    • fasting plasma-glucose(FPG) less than 7 mmol/L, or 2h p-glucose 7.8-11.1 mmol/L

    • anti-diabetic medication of any kind

    • able to provide informed consent

    Exclusion Criteria:
    • comorbidities that would prohibit participation in study procedures, including cardiovascular disease, hematological system disease or psychosis

    • females of childbearing potential who were pregnant, breast-feeding

    • infection within the 1 month

    • known or suspected abuse of alcohol or narcotics

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • China Academy of Chinese Medical Sciences

    Investigators

    • Study Director: Peijing Rong, doctor, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Peijing Rong, The deputy director of Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, China Academy of Chinese Medical Sciences
    ClinicalTrials.gov Identifier:
    NCT03343262
    Other Study ID Numbers:
    • ChinaACMS-4
    First Posted:
    Nov 17, 2017
    Last Update Posted:
    Nov 22, 2017
    Last Verified:
    Nov 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 22, 2017